metoprolol has been researched along with Depression in 12 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the influence of paroxetine on metoprolol concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given paroxetine as a co-treatment of depression." | 9.13 | Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ( Babak, S; Bergman, U; Bertilsson, L; Boldueva, S; Burbello, A; Goryachkina, K, 2008) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 7.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| " In a randomized, double-blind, placebo-controlled trial of 85 recently bereaved participants, we determined whether β-blocker (metoprolol 25 mg) and aspirin (100 mg) reduce cardiovascular risk markers and anxiety, without adversely affecting bereavement intensity." | 5.34 | The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial. ( Bartrop, R; Buckley, T; Dent, J; Fethney, J; Havyatt, J; McKinley, S; Mihailidou, AS; Morel-Kopp, MC; Prigerson, HG; Spinaze, M; Tofler, GH; Ward, C; Whitfield, V, 2020) |
| "To investigate the influence of paroxetine on metoprolol concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given paroxetine as a co-treatment of depression." | 5.13 | Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). ( Babak, S; Bergman, U; Bertilsson, L; Boldueva, S; Burbello, A; Goryachkina, K, 2008) |
| "After 4 days of drug treatment with comparable doses of propranolol (40 and 80 mg), metoprolol (50 and 100 mg), or placebo, mood (POMS) and anxiety states (STAI) were assessed in healthy volunteers, before and after 1 h of treadmill walking exercise at 50% maximum oxygen uptake." | 5.08 | Acute effects of beta blockade and exercise on mood and anxiety. ( Eagles, C; Ferner, R; Head, A; Kendall, MJ, 1996) |
| "This study assessed sex differences in cardiac and motor functions, quality of life (QoL), and mental status in Chinese chronic heart failure (CHF) patients after metoprolol treatment." | 3.91 | Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients. ( Meng, Y; Shu, Q; Wu, L; Zhang, Q; Zhang, R, 2019) |
| " Ginseng Fruit Saponin (GFS) and Metoprolol are two drugs which have beneficial effects on the cardiovascular system in Myocardial Infarction (MI) mice." | 3.91 | Antidepressant-like effects of ginseng fruit saponin in myocardial infarction mice. ( Ge, Y; Geng, Q; Liu, J; Liu, M; Zhang, L, 2019) |
| "Metoprolol is a selective β-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6)." | 1.40 | Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. ( Burkley, BM; Chapman, AB; Cooper-DeHoff, RM; Dwivedi, R; Garcia, S; Gong, Y; Gums, JG; Hamadeh, IS; Johnson, JA; Langaee, TY; Skaar, TC; Turner, ST, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, L | 3 |
| Zhang, Q | 3 |
| Shu, Q | 3 |
| Zhang, R | 3 |
| Meng, Y | 3 |
| Tofler, GH | 1 |
| Morel-Kopp, MC | 1 |
| Spinaze, M | 1 |
| Dent, J | 1 |
| Ward, C | 1 |
| McKinley, S | 1 |
| Mihailidou, AS | 1 |
| Havyatt, J | 1 |
| Whitfield, V | 1 |
| Bartrop, R | 1 |
| Fethney, J | 1 |
| Prigerson, HG | 1 |
| Buckley, T | 1 |
| Huang, J | 2 |
| Liu, M | 1 |
| Liu, J | 1 |
| Zhang, L | 1 |
| Geng, Q | 1 |
| Ge, Y | 1 |
| Hamadeh, IS | 1 |
| Langaee, TY | 1 |
| Dwivedi, R | 1 |
| Garcia, S | 1 |
| Burkley, BM | 1 |
| Skaar, TC | 1 |
| Chapman, AB | 1 |
| Gums, JG | 1 |
| Turner, ST | 1 |
| Gong, Y | 1 |
| Cooper-DeHoff, RM | 1 |
| Johnson, JA | 1 |
| Wagner, CC | 1 |
| Locher, P | 1 |
| Elke, B | 1 |
| Corti, N | 1 |
| Lebedeva, NB | 1 |
| Lebedev, OV | 1 |
| Berns, SA | 1 |
| Barbarash, LS | 1 |
| Barbarash, NA | 1 |
| Barbarash, OL | 1 |
| Goryachkina, K | 1 |
| Burbello, A | 1 |
| Boldueva, S | 1 |
| Babak, S | 1 |
| Bergman, U | 1 |
| Bertilsson, L | 1 |
| Assaykeen, TA | 1 |
| Michell, G | 1 |
| Howe, A | 1 |
| Head, A | 1 |
| Kendall, MJ | 1 |
| Ferner, R | 1 |
| Eagles, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses 2[NCT01203852] | Phase 4 | 839 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in glucose after treatment with study medication (NCT01203852)
Timeframe: after 6-8 weeks treatment
| Intervention | mg/dL (Mean) | |
|---|---|---|
| glucose response to metoprolol (n=365) | glucose response to chlorthalidone (n=318) | |
| Adverse Metabolic Effects | 1.02 | 5.12 |
Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment (NCT01203852)
Timeframe: after 6-8 weeks of treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| diastolic blood pressure response | systolic blood pressure response | |
| Chlorthalidone Only | -7.68 | -13.65 |
| Metoprolol + Chlorthalidone | -7.56 | -11.70 |
| Metorprolol Only | -7.97 | -7.45 |
1 review available for metoprolol and Depression
| Article | Year |
|---|---|
[Frequent drug interactions in old age].
Topics: Adrenergic beta-Antagonists; Age Factors; Antihypertensive Agents; Cytochrome P-450 Enzyme System; D | 2009 |
5 trials available for metoprolol and Depression
| Article | Year |
|---|---|
The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2020 |
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Area | 2008 |
Metoprolol in hypertension: an open evaluation.
Topics: Adult; Aged; Blood Pressure; Bronchial Spasm; Clinical Trials as Topic; Depression; Diuretics; Drug | 1982 |
Treatment of hypertension. Comparative trial of metoprolol Durules (once daily) and metoprolol tablets (twice daily).
Topics: Adult; Aged; Blood Pressure; Bronchial Spasm; Clinical Trials as Topic; Delayed-Action Preparations; | 1982 |
Acute effects of beta blockade and exercise on mood and anxiety.
Topics: Adrenergic beta-Antagonists; Adult; Affect; Age Factors; Anxiety; Body Weight; Confusion; Depression | 1996 |
6 other studies available for metoprolol and Depression
| Article | Year |
|---|---|
Sex-dependent changes in physical, mental, and quality of life outcomes in metoprolol-treated Chinese chronic heart failure patients.
Topics: Adult; Aged; Anxiety; Asian People; China; Chronic Disease; Depression; Female; Heart Failure; Heart | 2019 |
Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Anxiety; Chronic Disease; Depression; Female; Heart; Hea | 2019 |
Improvement in quality of life of Chinese chronic heart failure patients with neuropsychiatric complications over 12-months post-treatment with metoprolol.
Topics: Aged; Anti-Arrhythmia Agents; Anxiety; China; Chronic Disease; Depression; Female; Heart Failure; Hu | 2019 |
Antidepressant-like effects of ginseng fruit saponin in myocardial infarction mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depression; Disease Models, Anima | 2019 |
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytochrome P-450 CYP2D6; Depression; Fatigue; Female | 2014 |
[Interrelationship between electrophysiological markers of arrhythmogenicity and psychoemotional status of patients with myocardial infarction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmi | 2003 |